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ABSTRACT 
Introduction 
Hepatitis C (HCV) infection can cause cirrhosis, liver cancer and death in the absence of 
treatment.  Many people living in the UK but born overseas are believed to be infected with 
HCV although many are unlikely to know they are infected.  The aim of this study is to 
assess the potential for a case finding approach to be cost-effective and to estimate the 
value of further research. 
Method 
An economic evaluation and value of information analysis was undertaken by developing a 
model of HCV disease progression and by populating it with evidence from the published 
literature.  They were performed from a UK National Health Services cost perspective and 
outcomes were expressed in terms of quality-adjusted life-years (QALYs).  The comparator 
intervention was defined as the background rate of testing (ie. no intervention). 
Results 
The base case results generated an incremental cost-effectiveness ratio (ICER) of about 
£23,200 per additional QALY.  However, the ICER was shown to be particularly sensitive to 
HCV seroprevalence, the intervention effect / cost and the probability of treatment uptake.  
The value of information analysis suggested that approximately £4 million should be spent 
on further research. 
Discussion 
This evaluation demonstrates that testing UK migrants for HCV could be cost-effective.  
However, further research, particularly to refine estimates of the probability of treatment 
uptake once identified, the utility associated with sustained virological response and the cost 
of the intervention, would help to increase the robustness of this conclusion.  
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INTRODUCTION 
Hepatitis C virus (HCV) is common with an estimated 150 million [1] people chronically 
infected worldwide.  Infection causes progressive liver damage that, without treatment, may 
lead to cirrhosis, liver cancer and death [2].  Evidence suggests that antiviral treatment for 
hepatitis C (HCV) infection is highly cost-effective [3-5].  However, as disease progression is 
relatively slow, with approximately 20% of individuals progressing to cirrhosis within 
20 years, many individuals remain unaware they are chronically infected [6]. 
In the UK, injecting drug use is the major risk factor for acquiring HCV, but mortality and 
morbidity from chronic HCV is rising disproportionately among people from migrant 
communities [7].  It has been estimated that 30,000 individuals born overseas but living in 
the UK will develop chronic HCV, of whom 5,000 may develop cirrhosis in the next 20 years 
if untreated [8].  A policy of screening for hepatitis infection in people born outside the UK 
was rejected by the National Screening Committee in 2011, partly because evidence-based 
assessments of the costs of identifying and inviting individuals for tests were lacking [9]. 
More recently, the UK’s National Institute for Health and Care Excellence (NICE) has issued 
guidance relating to methods of increasing HCV case finding and treatment uptake within 
high risk and migrant communities [10].  However, the evidence base on which the 
recommendations were based was arguably weak and contained a number of important 
uncertainties [10].  The guidance is due to be considered for update in 2015. 
In this study we update the economic evaluation of a HCV case finding intervention for UK 
migrant populations that underpinned some of NICEs recommendations and estimate the 
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value of conducting further research.  The latter can be undertaken by incorporating a ‘value 
of information’ (VoI) analysis within the design of an economic evaluation.  Full details of this 
technique are available elsewhere [11, 12], but its results – the expected value of perfect 
information (EVPI) - can be interpreted as the maximum amount a funder should be willing to 
pay for further research given a threshold value of the cost of an additional unit of health, 
such as a Quality-Adjusted Life-Year (QALY).  A number of factors influence the EVPI, but 
the ability of research to change policy (ie. move a cost-effectiveness estimate to the 
opposite side of a threshold value such as £20,000 to £30,000 per additional QALY [13]) is 
central to it, as is the size of the population who could benefit from the research.  The EVPI 
can either be reported for the entire decision problem reflecting the joint uncertainties in all 
the sampled parameters, or for subsets of them, such as utilities, costs and probabilities.  
The latter is referred to as the expected value of partially perfect information (EVPPI), and its 
advantage is that disaggregating the EVPI in this manner means that the main drivers of any 
decision uncertainty are more readily identifiable and that subsequent research can be more 
directed. 
METHODS 
The economic evaluation was undertaken using a Markov modelling approach, where 
individuals move between a set of discrete health states, in this instance on a 6-monthly 
basis [14].  Health outcomes were expressed in terms of QALYs.  A UK’s National Health 
Service’s cost perspective was used and future costs and QALYs were discounted at 3.5% 
per annum.  All results are displayed in £ 2010 prices and a lifetime horizon was used.  
Uncertainty in the results was examined using deterministic and probabilistic sensitivity 
analysis (PSA); distributions shown in the tables relate to the PSA analysis.  .  The PSA 
results were also analysed using analysis of covariance techniques (ANCOVA).  The 
PSA / EVPI results were based on 1,000 sampled parameter values whereas the EVPPI 
results were based on 1,000 second order and 1,000 first order simulations.  HCV 
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transmission was not included in the model as nearly all infections are believed to occur in 
UK migrant populations before entering the country [2]. 
Intervention and target population 
A small number of hepatitis case finding methods have been studied in UK migrant 
populations [15-17], as identified in a recent systematic review [18].  This analysis, however, 
was based on a recent approach in which Pakistani/British Pakistani people registered at 
general practices (GPs) in London were written to and invited to ‘opt out’ of being tested for 
hepatitis B and C infection.  Those who did not opt out were telephoned and asked to attend 
a clinic for a test.  Although only an abstract was available, it was the most recent HCV-study 
to be identified and was UK-based [16].  The comparator programme was defined as the 
background likelihood of testing, or ‘no intervention’.  For the purposes of the VoI analysis, 
the population of interest was defined as migrants from the Indian subcontinent, primarily 
Bangladesh, India and Pakistan.  Evidence suggests that net migration to the UK from this 
region is about +93,000 people per annum [19, 20]. 
Model structure 
The Markov model included 12 main health states that were further subdivided according to 
whether or not HCV status was known; it is largely based on a previously used model 
structure (Figure 1) [3, 21]. Individuals were assumed to ‘enter’ the model in the uninfected, 
mild HCV, moderate HCV, and compensated cirrhosis (CC) heath states, all with unknown 
HCV Ab and RNA status.   
Although varied in a sensitivity analysis, the HCV status of individuals who developed DC, 
hepatocellular cirrhosis (HCC) and those receiving a liver transplant was assumed to be 
known at all times due to the severity of the disease and likely presentation.  Individuals 
were assumed to die from non-HCV related causes from all health states at an age adjusted 
rate.  Individuals who were diagnosed HCV Ab+ / RNA+ were eligible for antiviral treatment if 
they had mild HCV, moderate HCV, or CC.  In each case treatment was associated with a 
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chance of sustained viral response (SVR).  A single probability (0.45) of being referred for 
specialist care, attending it, and starting treatment was included as it is understood some 
individuals who are identified as eligible for treatment do not receive it [22].  Individuals who 
achieve SVR were assumed not to experience further liver disease progression. Those who 
failed antiviral treatment (non-SVRs) were assumed to have the same disease progression 
as those who had not received treatment.  Repeat treatment was not considered at any 
point.  The basic model logic was that increased testing leads to more or earlier antiviral 
treatment in a proportion of individuals who require it. 
Tests 
The basic test for HCV was assumed to be an antibody test (Ab).  Individuals who tested 
Ab+ were assumed to receive a PCR RNA test to confirm chronic infection.  Twenty-six 
percent of individuals who tested Ab+ were assumed to have spontaneously cleared their 
infection, and therefore to test PCR RNA- [23]. Both tests were assumed to be 100% 
accurate. 
Transition probabilities 
Transition probabilities represent the chance of moving between health states over the 
6 month cycle period.  Model values were based on those reported in a 2007 UK Health 
Technology Assessment report [3] (Table 1Table 1).  The probability of SVR was taken from 
studies using pegylated interferon [21, 24-27], and weighted according to genotype; 
evidence from the UK Health Protection Agency (HPA) suggests that people of South Asian 
or British Asian origin are 4 times more likely to have genotype 3 than genotype 1 [7].  The 
probability of SVR for people with CC was assumed to be lower than for people with mild or 
moderate HCV [28]. 
HCV seroprevalence 
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Recent UK HPA [7] data suggests that of 52,533 HCV tests undertaken by people with 
South / British Asian backgrounds, 1,658 were Ab+ (3.2%).  Values of 1% and 5% were 
used in the sensitivity analysis. 
The background rate of testing, in the absence of the intervention was also estimated using 
the HPA data.  First, the total population of England and Wales is estimated to be 
56.1 million of which 6.8% of people are estimated to be Bangladeshi, Pakistani or Indian.  
Second, HPA data suggests that in 2010, 52,533 of likely South-Asian descent were tested 
for HCV antibody; the data is thought to relate to about a third of all tests in England.  Thus, 
the base case annual background rate of testing was estimated to be 
([[1/0.333]*52,533]/[56.1 million*0.068]) = 0.041.  A small study in six UK primary care 
practices also found that less than 5% of migrants were tested for HCV (Shivani Datta, paper 
in review). 
A potential complication with this evaluation is that the costs and benefits of testing and 
treatment might not be fully realised from a UK NHS perspective since individuals could 
leave the country sometime after a diagnosis of chronic infection.  This possibility was not 
included in the base case analysis, but was investigated in a sensitivity analysis by 
assuming 1% of people left the country every 6 months irrespective of HCV status. 
Intervention effect 
The probability of testing in the intervention arm was based on the recent ‘opt out’ option 
described by Lewis et al [16].  Approximately 20% (223/1,134) of all eligible individuals were 
tested; many GP records did not contain up-to-date contact details largely explaining the 
modest uptake.  This was assumed to be the intervention effect during the first model cycle, 
reverting to the background probability of testing after this time. 
HCV treatment 
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In the base case individuals identified as HCV RNA+ were assumed to receive an average 
of 6 months treatment with pegylated interferon and ribavirin.  The mean probabilities of SVR 
for people with mild / moderate disease or CC with genotype 2/3 infection were estimated to 
be 0.8 and 0.6 respectively [21, 24-26].  Both probabilities were assumed to lower for 
genotype 1 [28] infection and a sensitivity analysis was run in which treatment was assumed 
to include the addition of boceprevir / telaprevir. 
Initial probabilities 
Direct evidence on the numbers in each health state for the undiagnosed HCV chronically 
infected migrants could not be identified.  Therefore this distribution was estimated based on 
the assumed seroprevalence of HCV and a modelling exercise to estimate baseline steady 
state distributions amongst current UK intravenous drug users (IDUs) [29].  However, as it is 
acknowledged that the uncertainty around these estimates is high, the probabilities were 
sampled.  Not that the distribution is likely to underestimate the proportion of migrants in 
later disease stages, hence further deterministic sensitivity analysis was undertaken by 
assuming 10% of individuals had decompensated cirrhosis (DC) when testing HCV RNA+. 
Utilities 
Utility values can be viewed as the health-related quality-of-life associated with particular 
health states.  The inputted values ; they have been used in a number of UK technology 
assessment reports (eg Shepherd et al [3]) but were originally derived from were taken from 
a UK RCT of mild disease [4] and UK study enrolling individuals with latter stage disease 
[30]Shepherd [3]  (Table 2Table 2). 
Costs 
The costs of the intervention described above were not recorded.  Moreover, determining the 
cost of a hepatitis case finding intervention from the literature is difficult, since reported 
interventions are idiosyncratic, often brief in their description and do not report resource use 
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in any detail.  Therefore, for the purposes of the base case analysis, an intervention cost of 
£20 per eligible person was assumed, excluding the cost of any tests and treatments.  Thus, 
if 100 individuals were eligible for testing, the total cost of the intervention was £2,000 
irrespective of how many people subsequently attended for a test.  The importance of this 
assumption was assessed in the sensitivity analysis and given the extent of uncertainty, a 
relatively high standard error was assumed for the probabilistic analysis (Table 3Table 3).  
The costs of antiviral treatment and health-state specific costs were taken from a number of 
well documented sources, inflated to 2010 £ where appropriated using the UKs Hospital and 
Community Health Services Pay and Prices Index [31] (Table 3Table 3). 
RESULTS 
The base case results produced mean per individual non-intervention and intervention costs 
of £373 and £425 respectively with associated QALYs of 17.759 and 17.762, producing an 
incremental cost-effectiveness ratio (ICER) of about £23,200 per additional QALY.  The cost-
effectiveness acceptability curve, however, showed a large degree of uncertainty around this 
result; the probability the intervention is cost-effective at a £20,000 to £30,000 per additional 
QALY threshold was between 35 and 71% (Figure 2Figure 2).  The HCV seroprevalence 
required to generate incremental cost per QALYs of £20,000 or £30,000 were 4.4% or 2.1% 
respectively.  The corresponding threshold values for the probability of testing (ie. the 
intervention effect) were 0.28 and 0.12 respectively. 
ANCOVA 
The ANCOVA results detail the contribution of each of the probabilistic input parameters in 
the PSA simulations to the incremental costs (mean £51.3; 95% 50.8, 51.8) and QALYs 
(mean 0.0022; 95% 0.00219, 0.00225) (Figure 3Figure 3).  They show that 43% of the 
variation in incremental costs was attributable to the variation in the intervention cost.  
However, an even greater proportion of the variation (51%) was attributable to the 
background probability of testing.  It was also responsible for the largest variation in the 
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incremental QALYs.  None of transition probabilities representing the natural history of the 
disease accounted for a significant amount of the variation in the costs or QALYs. 
One-way deterministic sensitivity analysis 
The sensitivity analysis showed that the results were particularly affected by a number of 
variables, including HCV seroprevalence, the intervention effect / cost, the probability of 
treatment uptake and the probability of leaving the UK (Table 4Table 4).  Increasing Tthe 
cost of antiviral treatment or including the addition of boceprevir / telaprevir had little impact 
on the cost-effectiveness estimates.results. 
EVP(P)I 
Assuming the intervention remains a viable option for 10 years, it produces a total population 
EVPI of around £4 million over this period in the base case at a £30,000 QALY threshold 
(Table 5Table 5).  However, the EVPPI analysis suggests that further research into the 
probability of treatment uptake, the utility associated with the SVR health states and the 
intervention cost would be of most value. 
DISCUSSION 
There are over 1.4 million people from the Indian subcontinent living in the UK with a net of 
over +90,000 long term migrants arriving each year.  As HCV is endemic in parts of this 
region, many will be infected although unaware of their status.  The UK does not currently 
have a national policy of screening migrants for HCV, partly because of lack of evidence on 
cost-effectiveness [9].  However, the results from this economic evaluation suggest that an 
opt-out GP case finding intervention could be cost-effective but that there is a large degree 
of uncertainty around this conclusion and value in conducting further research. 
The major strength of this study is that it is based on an established model of HCV disease 
progression.  Its major limitations are that a number of parameters and associated 
uncertainty bounds lacked empirical evidence and were based on opinion.  Moreover, the 
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evaluation did not incorporate the possibility of simultaneously testing for hepatitis B (HBV) 
infection which is also thought to be endemic in many parts of the Indian subcontinent [2].  
However, if it had, then logic dictates the cost-effectiveness estimate would improve since 
the costs of detection are effectively divided across two infections and treatment for HBV 
infection has been shown to be cost-effective [32, 33].  It would also mean that the EVPI 
would decrease since an improvement in cost-effectiveness would lessen the potential 
impact of further information. 
An important issue is that we have evaluated the potential costs and effects of a particular 
‘one off’ case finding intervention [16].  However, the results from two other much less 
effective interventions are also reported in the same abstract.  Thus, while the cost-
effectiveness of the GP intervention appears to be reasonable given the base case input 
assumptions, the likelihood that other case finding approaches are cost-effective is much 
less clear. 
The EVPI analysis showed that the total value of further research into the costs and effects 
of the case finding intervention should not exceed £4 million over the next 10-years if HCV 
seroprevalence is thought to be around 3.2% at a cost per additional QALY threshold of 
£20,000.  However, the EVPPI analysis suggests that most of the uncertainty is being driven 
by the intervention cost (£0.43 million), the probability of treatment uptake (£0.21 million) and 
the utility associated with the SVR health states (£0.87 million). in this order.  Thus, 
improving the accuracy of these parameters should be the priority if the aim is to generate 
more certain cost-effectiveness estimates in the future. 
The value of further research into the effectiveness of case finding, in terms of an increased 
probability of testing as a result of the case finding intervention, was noticeably small.  This 
finding appears counterintuitive but is firstly explained by the large population size in the 
Lewis study (n=1,134), meaning the level of uncertainty in the parameter was already 
relatively low.  Secondly, the lowest sampled probability of testing following the intervention 
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was 0.16; at this level the intervention is already cost-effective.  Indeed, this illustrates the 
advantage of EVPI analysis over more traditional sensitivity analysis techniques, as its value 
reflects the ability of research to alter policy decisions rather than merely reflecting the 
impact of different parameter values on the actual cost-effectiveness estimate. 
While there have been a number of economic evaluations of HCV case finding interventions 
in former or current (IDUs) [34], and others relating to HBV, only one could be found that 
evaluated an intervention to find HCV cases that was at least in part aimed at migrant 
populations [35].  This Dutch study evaluated the outcomes of a national intervention to 
increase awareness of possible HCV infection in all high risk groups and a support 
programme that provided training sessions for GPs.  The base case ICER was 
approximately €12,000 per additional QALY.  While this value is somewhat lower than our 
own, the QALYs were discounted at 1.5% rather than 3.5% per annum which would bring 
the results approximately into line. 
There are reasons to believe the EVPI and EVPPI values could be conservative.  First, the 
population projections are based on net rather than total immigration figures, the latter is 
nearer 120,000 per annum).  Second, the population projections were based on figures from 
the Indian subcontinent while people migrating from other countries might also benefit from 
additional research.  Third, the assessment was based on 10-year projections but 
immigration from HCV endemic countries is likely to continue past this time.  Fourth, while 
we have sampled ‘parameter’ uncertainty, we have not allowed for the fact that the study 
from which the effectiveness estimate is derived is a single large non-controlled study.  Thus 
we may have undervalued the uncertainty in effectiveness estimate and as a consequence, 
the benefits of further research into the accuracy of this parameter.  Last, an interesting 
moral / ethical issue is whether or not to account for, and to exclude, the potential 
downstream costs and QALYs relating to people who leave the UK after being tested.  In the 
base case analysis we chose not to include these outcomes, but we note that while their 
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exclusion would decrease the mean cost-effectiveness estimate, the EVPI would increase 
since the ICER is pushed neared to a £30,000 per additional QALY threshold.  
While the precise level of HCV seroprevalence is likely to vary by community setting [2], it is 
an important determinant of the cost-effectiveness of identification strategies, the ICER 
increased to £45,000 when 1% was assumed.  However, if it is thought to be 2% or higher 
within any given population, then based on current evidence, we believe there is every 
possibility the GP-based intervention described herein is cost-effective at a £30,000 per 
additional QALY threshold. 
NICE has recently concluded that migrants from HCV endemic countries should be tested 
for active infection, and case finding is recommended [10].  The UKs National Institute for 
Health Research has recently commissioned research on finding cases of hepatitis infection 
in UK migrant populations, at a cost of approximately £2 million (RP-PG-1209-10038) [36].  
We broadly agree with NICEs recommendation and the funding decision for further research, 
but emphasise the importance of collecting information on parameters such as the 
background probability of testing and the intervention cost, not just the immediate 
intervention effect. 
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Table 1: Base case probability inputs (suggested online supplementary material) 
Parameter Mean Distribution Source 
Transition probabilities    
 Mild to moderate* 0.025 Beta~(38.086, 1485.316) Shepherd, Martin [3, 21] 
 Moderate to CC* 0.04 Beta~(26.905 700.2582) Shepherd, Martin [3, 21] 
 CC to DC* 0.053 Beta~(14.617, 260.1732) Shepherd, Martin [3, 21] 
 CC to HCC* 0.014 Beta~(1.9326, 136.1074) Shepherd, Martin [3, 21] 
 DC to HCC* 0.014 Beta~(1.9326, 136.1074) Shepherd, Martin [3, 21] 
 DC to death* 0.13 Beta~(147.03, 983.97) Shepherd, Martin [3, 21] 
 DC to liver transplant (LT)* 0.03 Beta~(6.5256, 210.9945) Shepherd, Martin [3, 21] 
 HCC to death* 0.43 Beta~(117.1, 155.23) Shepherd, Martin [3, 21] 
 1st 6 months post LT to death* 0.21 Beta~(16.276, 61.2294) Shepherd, Martin [3, 21] 
 >6 months post LT to death* 0.057 Beta~(22.902, 378.8825) Shepherd, Martin [3, 21] 
% Sustained viral response**    
 Mild / mod. genotype 1 0.45 Uniform~(0.40, 0.50) Martin and others [21, 
24-28] 
 Mild / mod. genotype 2/3 0.80 Uniform~(0.75, 0.85) Martin and others [21, 
24-27] 
 CC genotype 1 0.25 Uniform~(0.20, 0.25) Martin and others [21, 
24-28] 
 CC genotype 2/3 0.60 Uniform~(0.55, 0.65) Martin and others [21, 
24-27] 
Proportion with genotype 1 0.20 Fixed UK HPA [7] 
Intervention effect (1st cycle only, absolute 
probability of testing) 
0.20 Beta~(n=1,134, r=223) Lewis et al [16] 
Probability of referral, attendance and 
treatment 
0.45 Beta~(n=56, r=25) Irving et al [22] 
Background testing 0.041 Uniform~(0.001,0.081) HPA [7] and assumptions 
Proportion of HCV Ab+ who are RNA- 0.26 Beta~(156.9, 446.5) Micallef et al [23] 
Initial probabilities    
 Uninfected 1-
seroprevalence 
 - 
 HCV Ab+ / PCR- pAbPCR+ *seroprevalence - 
 Mild HCV 0.63*(1-
pAvPCR) 
Dirichlet(0.63,0.24,0.17) Martin [21] and 
assumptions 
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 Moderate HCV 0.24*(1-
pAvPCR) 
Dirichlet(0.63,0.24,0.17) Martin [21] and 
assumptions 
 CC 0.17*(1-
pAvPCR) 
Dirichlet(0.63,0.24,0.17) Martin [21] and 
assumptions 
HCV seroprevalence 3.2% - HPA [7] and assumptions 
*probabilities are annual, converted to 6 monthly probabilities in the model using 1-(1-prob)^0.5; Residual equals 
one minus the sum of the other related probabilities; **based on a combination therapy of pegylated interferon 
plus ribavirin; “where prevalence indicates HCV seroprevalence 
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Table 2: Base case utility values, all taken from Wright [4] which are repeated in Shepherd [3] unless otherwise indicated 
(suggested online supplementary material) 
Utility value Mean Distribution 
Uninfected   
 Age 0-44 years 0.91 - 
 Age 45-54 years 0.85 - 
 Age 55-64 years 0.80 - 
 Age 65-74 years 0.78 - 
 Age 75+ 0.73  
Mild HCV 0.77 Beta~(521.238, 155.6943) 
Mild HCV SVR 0.82 Beta~(65.8678, 14.4588) 
Moderate HCV 0.66 Beta~(168.246, 86.6723) 
Moderate HCV SVR 0.72 Beta~(58.0608, 22.5792) 
Compensated cirrhosis 0.55 Beta~(47.1021, 38.5381) 
Compensated cirrhosis SVR 0.61 Beta~(58.0476, 37.1124) 
Decompensated cirrhosis [30] 0.45 Beta~(123.75, 151.25) 
Hepatocellular carcinoma [30] 0.45 Beta~(123.75, 151.25) 
Liver transplant (1st year) [30] 0.45 Beta~(123.75, 151.25) 
Liver transplant (subsequent years) [30] 0.66 Beta~(32, 16) 
Utilities were calculated by multiplying the HCV uninfected age adjusted value by the relevant health state.  For example, the 
utility of a 76 year old person with mild HCV = 0.73 x 0.77 = 0.56 
  
Miners p.18 
 
 
 
 
Table 3: Base case cost inputs in 2010 prices unless otherwise stated (suggested online supplementary material) 
Cost Mean (£) Distribution Source 
Health State*    
  Annual mild HCV 138 Gamma~(25.7, 0.1862) Martin, Shepherd [3, 29] 
  Annual moderate HCV 717 Gamma~(88.85, 0.1239) Martin, Shepherd [3, 29] 
  Annual compensated cirrhosis 1,138 Gamma~(24.234, 0.0213) Martin, Shepherd [3, 29] 
  Annual decompensated cirrhosis 9,120 Gamma~(36.0249, 0.004) Martin, Shepherd [3, 29] 
  Annual hepatocellular carcinoma 8,127 Gamma~(18.108, 0.0022) Martin, Shepherd [3, 29] 
  Liver transplant (per transplant) 27,330 Gamma~(89.7536, 0.0033) Martin, Shepherd [3, 29] 
  Year following transplant 9,458 Gamma~(13.7788, 0.0015) Martin, Shepherd [3, 29] 
  Annual post transplant 1,385 Gamma~(15.2189, 0.011) Martin, Shepherd [3, 29] 
  Annual mild SVR 259 Gamma~(28.8141, 0.10) Martin, Shepherd [3, 29] 
  Annual moderate SVR 717 Gamma~(89.004, 0.124) Martin, Shepherd [3, 29] 
  Annual cirrhosis SVR 1138 Gamma~(25.81, 0.0227) Martin, Shepherd [3, 29] 
Antiviral treatment (for 6 months)+ 5,612 Uniform~(4,806, 6,418) Martin and BNF [21, 37] 
PCR test (per test) 70 - Martin [21] 
HCV antibody test (per test) 10 - Assumption 
Nurse (GP practice, per test) 9.75 - Curtis [38] 
Intervention (per eligible person)** 20 Gamma~(4, 0.22) Assumption 
*All health state costs are stated in 2003/4 prices and are inflated to 2010 prices in the analysis ** Excludes the 
costs of the test itself; +treatment is with pegylated interferon and ribavirin 
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Table 4: One way sensitivity analysis 
Parameter Base case 
value 
ICER (£) 
Base case  23,200 
HCV Ab+ prevalence  3.2%  
 1%  45,700 
 5%  19,300 
Intervention cost per eligible person £20*  
 £10  18,300 
 £30  27,700 
Intervention effect (absolute probability of testing in first 6 months) 0.197*  
 0.1  34,500 
 0.3  19,500 
Treatment referral and attendance (probability of treatment uptake) 0.45*  
 0.33  31,000 
 0.66  15,600 
Antiviral treatment costs – pegylated interferon and ribavirin £5,612*  
 £7,500  23,900 
Addition of boceprevir / telaprevir for genotype 1   
 £19,000 additional cost, probability SVR 0.63 (mild / moderates) and 
 probability SVR 0.45 for compensated cirrhosis  
  
 23,740 
Initial probability of having decompensated cirrhosis  0  
 0.10   26,700 
6 Monthly probability of permanently leaving the UK** 0  
 0.01  32,500 
*mean distribution value; **taken to be equivalent to no further costs or QALYs after ‘exit’ 
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Table 5: Expected value of perfect (EVPI) and partial (EVPPI) information results at a willingness to pay (WTP) of £30,000 
per QALY and base case assumptions 
Parameter Population EVP(P)I (million) 
Overall decision level £3.80 
 WTP £20,000 per additional QALY £4.07 
 1% HCV Ab+ seroprevalence £1.13 
 1% HCV Ab+ seroprevalence and WTP £20,000 £0.10 
Intervention effect (absolute probability of testing) Negligible 
Probability of treatment uptake £0.21 
Background probability of testing Negligible 
Utilities £1.07 
 SVR health states £0.87 
Intervention cost £0.43 
Disease costs Negligible 
Transition probabilities £0.02 
Initial distribution across HCV disease states Negligible 
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